Product Code: MRFR/CnM/6810-CR
Market Overview
The phase change material market size is projected to witness a notable market expansion at a CAGR of 17.90% during the review period to surpass USD 49,021.39 thousand by the end of 2028. PCMs are bio-based materials, for example, unsaturated fats or oils that are utilized as a shell material for drug conveyance. Phase change materials are inexhaustible, reusable, and motor and fuel free, making them ideal for immunization transportation. Phage change materials (PCMs) are substances which assimilate or deliver a lot of supposed 'inactive' heat when they go through an adjustment of their actual state, i.e., from strong to fluid as well as the other way around. Offering a scope of warm administration arrangements, PCMs work with the capacity to oversee request between energy prerequisites and utilization.
The global phase change material market is anticipated to register a healthy market expansion during the review period owing to the highest market value of USD 13,397.69 thousand in 2020. In clinical area, the PCMs are widely utilized for transportation of blood, antibodies, and temperature-touchy drugs, surgical tables, hot-cold treatments, treatment of birth asphyxia, and medication conveyance. However, certain impediments related with the item are cooling impact comes from underneath the item, which makes a bigger temperature degree from the highest items to the lower items. Such detriments connected with the utilization of PCM items is a limitation for the market development.
Market Segmentation
The segmental analysis of the global phase change material is classified by type, equipment, temperature range, and end-user.
The type of segment is categorized in terms of Organic, Inorganic, and Eutectic. In terms of equipment the market is classified into Refrigerators, Cold Boxes, and Carriers. By Temperature Range segment the market has been divided into -20 to -35 deg C, 2 to 8 deg C, 10 to 15 deg C, and Others.
The End-user segment of the global phase change material market is segmented as Biopharmaceutical Companies, Hospitals, Medical Laboratories, and Others.
Regional Analysis
Asia-pacific represented the biggest market share and is projected to display a sound CAGR throughout the approaching years. The development of the area can be related with the development of the drug business in China, India, and Japan. Also, the market in North America is powered by admittance to high-esteem drugs, antibody transportation, medical services mindfulness, high per capita consumption on medical care, and the high GDP of the locale. In Europe, the presence of many organizations and SMEs that production and supply phase change materials is supposed to give hopeful development to Europe market. Additionally, The European Health Union executed a methodology in 2020, which incorporates an expansive extent of regions, for example, innovative work of drugs, lab testing, clinical preliminaries, marketing approval, producing, wellbeing innovation evaluation, valuing and repayment, protected innovation insurance, and the section of meds, incorporating generics and biosimilars in the market.
Major Players
The prominent players of the gloal phase change material market is Croda International Plc (UK), PureTemp (US), Sasol (South Africa), Henkel AG & Co. KGaA (Germany), Cryopak (US), Teappcm (US), Rubitherm (Germany), Cold Chain Technologies (US), Merck KGaA (Germany), Pluss Advanced Technologies Pvt. Ltd (India), and PCM Products Ltd (UK).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 15
- 1.1 MARKET ATTRACTIVENESS ANALYSIS 17
- 1.1.1 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TYPE 18
- 1.1.2 GLOBAL PHASE CHANGE MATERIALS MARKET, BY EQUIPMENT 19
- 1.1.3 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TEMPERATURE RANGE 20
- 1.1.4 GLOBAL PHASE CHANGE MATERIALS MARKET, BY END-USER 21
- 1.1.5 GLOBAL PHASE CHANGE MATERIALS MARKET, BY REGION 22
2 MARKET INTRODUCTION 23
- 2.1 DEFINITION 23
- 2.2 SCOPE OF THE STUDY 23
- 2.3 MARKET STRUCTURE 23
3 RESEARCH METHODOLOGY 24
- 3.1 RESEARCH PROCESS 24
- 3.2 PRIMARY RESEARCH 25
- 3.3 SECONDARY RESEARCH 26
- 3.4 MARKET SIZE ESTIMATION 26
- 3.5 TOP-DOWN AND BOTTOM-UP APPROACH 27
- 3.6 FORECAST MODEL 28
- 3.7 LIST OF ASSUMPTIONS & LIMITATIONS 29
4 MARKET DYNAMICS 30
- 4.1 INTRODUCTION 30
- 4.2 DRIVERS 31
- 4.2.1 GROWING DEMAND FOR PCMS IN DRUG DELIVERY AND VACCINE AND MEDICINAL TRANSPORT 31
- 4.2.2 USE OF PCMS FOR THERAPEUTIC HYPOTHERMIA IN NEONATAL AND RHEUMATIC DISEASES 32
- 4.3 RESTRAINTS 33
- 4.3.1 DISADVANTAGES ASSOCIATED WITH PCM PRODUCTS 33
- 4.4 OPPORTUNITIES 34
- 4.4.1 INCREASING NUMBER OF CLINICAL TRIALS AND DEVELOPMENT OF NEW THERAPIES 34
- 4.5 CHALLENGES 35
- 4.5.1 REGULATIONS IN THE COLD SUPPLY CHAIN 35
5 MARKET FACTOR ANALYSIS 36
- 5.1 SUPPLY CHAIN ANALYSIS 36
- 5.1.1 RAW MATERIAL SUPPLIERS 37
- 5.1.1.1 INORGANIC 37
- 5.1.1.2 ORGANIC 37
- 5.1.1.3 EUTECTIC 38
- 5.1.2 PHASE CHANGE MATERIALS PRODUCERS 38
- 5.1.3 DISTRIBUTION & SALES CHANNEL 38
- 5.1.4 END-USER 39
- 5.2 PORTER'S FIVE FORCES ANALYSIS 39
- 5.2.1 THREAT OF NEW ENTRANTS 40
- 5.2.2 BARGAINING POWER OF SUPPLIERS 40
- 5.2.3 THREAT OF SUBSTITUTES 40
- 5.2.4 BARGAINING POWER OF BUYERS 40
- 5.2.5 INTENSITY OF RIVALRY 40
- 5.3 IMPACT OF COVID 19 OUTBREAK ON GLOBAL PHASE CHANGE MATERIALS MARKET 40
- 5.3.1 IMPACT ON GLOBAL ECONOMY 40
- 5.3.2 IMPACT ON SUPPLY CHAIN OF PHASE CHANGE MATERIALS MARKET 41
- 5.3.3 MAJOR GOVERNMENT POLICIES TO COUNTER THE IMPACT OF COVID-19 42
- 5.3.3.1 MONETARY AND MACRO-FINANCIAL 46
- 5.3.4 QUALITATIVE ANALYSIS ON CHANGES IN DEMAND FROM END-USERS 47
- 5.3.4.1 BIOPHARMACEUTICAL COMPANIES 47
- 5.3.4.2 HOSPITALS 47
- 5.3.4.3 MEDICAL LABORATORIES 47
6 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TYPE 48
- 6.1 INTRODUCTION 48
- 6.2 ORGANIC 49
- 6.3 INORGANIC 50
- 6.4 EUTECTIC 51
7 GLOBAL PHASE CHANGE MATERIALS MARKET, BY EQUIPMENT 52
- 7.1 INTRODUCTION 52
- 7.2 REFRIGERATORS 53
- 7.3 COLD BOXES 54
- 7.4 CARRIERS 55
8 GLOBAL PHASE CHANGE MATERIALS MARKET, BY TEMPERATURE RANGE 56
- 8.1 INTRODUCTION 56
- 8.2 -20 TO -35 DEG C 57
- 8.3 2 TO 8 DEG C 58
- 8.4 10 TO 15 DEG C 59
- 8.5 OTHERS 60
9 GLOBAL PHASE CHANGE MATERIALS MARKET, BY END-USER 61
- 9.1 INTRODUCTION 61
- 9.2 BIOPHARMACEUTICAL COMPANIES 62
- 9.3 HOSPITALS 63
- 9.4 MEDICAL LABORATORIES 64
- 9.5 OTHERS 65
10 GLOBAL PHASE CHANGE MATERIALS MARKET, BY REGION 66
- 10.1 INTRODUCTION 66
- 10.2 NORTH AMERICA 68
- 10.2.1 US 71
- 10.2.2 CANADA 73
- 10.3 EUROPE 75
- 10.3.1 GERMANY 78
- 10.3.2 UK 80
- 10.3.3 FRANCE 82
- 10.3.4 SPAIN 84
- 10.3.5 ITALY 86
- 10.3.6 REST OF EUROPE 88
- 10.4 ASIA-PACIFIC 90
- 10.4.1 CHINA 93
- 10.4.2 INDIA 95
- 10.4.3 JAPAN 97
- 10.4.4 SOUTH KOREA 99
- 10.4.5 REST OF ASIA-PACIFIC 101
- 10.5 LATIN AMERICA 103
- 10.5.1 BRAZIL 106
- 10.5.2 MEXICO 108
- 10.5.3 ARGENTINA 110
- 10.5.4 REST OF LATIN AMERICA 112
- 10.6 MIDDLE EAST & AFRICA 114
- 10.6.1 GCC COUNTRIES 117
- 10.6.2 SOUTH AFRICA 119
- 10.6.3 REST OF THE MIDDLE EAST & AFRICA 121
11 COMPETITIVE LANDSCAPE 123
- 11.1 INTRODUCTION 123
- 11.2 MARKET STRATEGY ANALYSIS 123
- 11.3 COMPETITIVE BENCHMARKING 124
12 COMPANY PROFILES 125
- 12.1 CRODA INTERNATIONAL PLC 125
- 12.1.1 COMPANY OVERVIEW 125
- 12.1.2 FINANCIAL OVERVIEW 126
- 12.1.3 PRODUCTS OFFERED 126
- 12.1.4 KEY DEVELOPMENTS 127
- 12.1.5 SWOT ANALYSIS 127
- 12.1.6 KEY STRATEGIES 127
- 12.2 SASOL 128
- 12.2.1 COMPANY OVERVIEW 128
- 12.2.2 FINANCIAL OVERVIEW 128
- 12.2.3 PRODUCTS OFFERED 129
- 12.2.4 KEY DEVELOPMENTS 129
- 12.2.5 SWOT ANALYSIS 129
- 12.2.6 KEY STRATEGIES 130
- 12.3 HENKEL AG & CO. KGAA 131
- 12.3.1 COMPANY OVERVIEW 131
- 12.3.2 FINANCIAL OVERVIEW 131
- 12.3.3 PRODUCTS OFFERED 132
- 12.3.4 KEY DEVELOPMENTS 132
- 12.3.5 SWOT ANALYSIS 132
- 12.3.6 KEY STRATEGIES 133
- 12.4 CRYOPAK 134
- 12.4.1 COMPANY OVERVIEW 134
- 12.4.2 FINANCIAL OVERVIEW 134
- 12.4.3 PRODUCTS OFFERED 134
- 12.4.4 KEY DEVELOPMENTS 134
- 12.4.5 SWOT ANALYSIS 135
- 12.4.6 KEY STRATEGIES 135
- 12.5 MERCK KGAA 136
- 12.5.1 COMPANY OVERVIEW 136
- 12.5.2 FINANCIAL OVERVIEW 137
- 12.5.3 PRODUCTS OFFERED 137
- 12.5.4 KEY DEVELOPMENTS 138
- 12.5.5 SWOT ANALYSIS 138
- 12.5.6 KEY STRATEGIES 138
- 12.6 PLUSS ADVANCED TECHNOLOGIES PVT. LTD 139
- 12.6.1 COMPANY OVERVIEW 139
- 12.6.2 FINANCIAL OVERVIEW 139
- 12.6.3 PRODUCTS OFFERED 139
- 12.6.4 KEY DEVELOPMENTS 140
- 12.6.5 SWOT ANALYSIS 141
- 12.6.6 KEY STRATEGIES 141
- 12.7 PURETEMP 142
- 12.7.1 COMPANY OVERVIEW 142
- 12.7.2 FINANCIAL OVERVIEW 142
- 12.7.3 PRODUCTS OFFERED 142
- 12.7.4 KEY DEVELOPMENTS 142
- 12.7.5 SWOT ANALYSIS 143
- 12.7.6 KEY STRATEGIES 143
- 12.8 TEAPPCM 144
- 12.8.1 COMPANY OVERVIEW 144
- 12.8.2 FINANCIAL OVERVIEW 144
- 12.8.3 PRODUCTS OFFERED 144
- 12.8.4 KEY DEVELOPMENTS 144
- 12.8.5 SWOT ANALYSIS 145
- 12.8.6 KEY STRATEGIES 145
- 12.9 RUBITHERM 146
- 12.9.1 COMPANY OVERVIEW 146
- 12.9.2 FINANCIAL OVERVIEW 146
- 12.9.3 PRODUCT OFFERINGS 146
- 12.9.4 KEY DEVELOPMENTS 147
- 12.9.5 SWOT ANALYSIS 147
- 12.9.6 KEY STRATEGIES 147
- 12.10 PCM PRODUCTS LTD 148
- 12.10.1 COMPANY OVERVIEW 148
- 12.10.2 FINANCIAL OVERVIEW 148
- 12.10.3 PRODUCT OFFERINGS 148
- 12.10.4 KEY DEVELOPMENTS 149
- 12.10.5 SWOT ANALYSIS 149
- 12.10.6 KEY STRATEGIES 149
- 12.11 COLD CHAIN TECHNOLOGIE 150
- 12.11.1 COMPANY OVERVIEW 150
- 12.11.2 FINANCIAL OVERVIEW 150
- 12.11.3 PRODUCT OFFERINGS 150
- 12.11.4 KEY DEVELOPMENTS 151
- 12.11.5 SWOT ANALYSIS 151
- 12.11.6 KEY STRATEGIES 151
13 APPENDIX 152
- 13.1 REFERENCES 152
- 13.2 RELATED REPORTS 153